Drug Profile
GM 1892
Latest Information Update: 07 Feb 2001
Price :
$50
*
At a glance
- Originator Glycomed
- Class Anti-ischaemics
- Mechanism of Action Glycosaminoglycan inhibitors; Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued End-organ damage; Reperfusion injury
Most Recent Events
- 07 Feb 2001 Discontinued-Preclinical for End-organ damage in USA (Unknown route)
- 07 Feb 2001 Discontinued-Preclinical for Reperfusion injury in USA (Unknown route)
- 28 Apr 1998 Preclinical development for Reperfusion injury in USA (Unknown route)